Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

This study is testing whether a drug called chidamide (an epigenetic medication that affects how genes are expressed) can prevent acute myeloid leukemia (AML) from coming back in high-risk patients after they have received a stem cell transplant from a donor (allo-HSCT). **You may be eligible if...** - You are between 18 and 65 years old - You have high-risk AML and have undergone a successful donor stem cell transplant - You have achieved complete remission and your blood counts have recovered - You have no active graft-versus-host disease (GVHD) or central nervous system involvement - Your major organs are functioning well **You may NOT be eligible if...** - You have serious heart, liver, or kidney disease - You have active, uncontrolled infection - You have poor graft function after transplant - You have active GVHD - You have HIV, active hepatitis B or C, or a history of prolonged QT syndrome - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.